Alex Thompson
Stock Analyst at Stifel
(2.61)
# 2,269
Out of 5,022 analysts
37
Total ratings
57.14%
Success rate
2.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $34.42 | +88.84% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $26.20 | -4.58% | 4 | Sep 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $208.43 | +21.86% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.83 | +180.97% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $59.89 | -8.16% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $13.67 | +163.35% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $44.43 | +35.04% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $25.51 | +92.12% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $799.56 | -37.47% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $18.92 | +185.49% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $3.71 | -46.09% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $10.66 | +547.28% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.91 | -47.64% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $21.37 | +87.18% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $26.35 | +1,114.42% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $17.35 | +95.97% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.49 | +2,114.77% | 1 | Dec 14, 2022 |
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $34.42
Upside: +88.84%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $26.20
Upside: -4.58%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $208.43
Upside: +21.86%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.83
Upside: +180.97%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $59.89
Upside: -8.16%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $13.67
Upside: +163.35%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $44.43
Upside: +35.04%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $25.51
Upside: +92.12%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $799.56
Upside: -37.47%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $18.92
Upside: +185.49%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $3.71
Upside: -46.09%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $10.66
Upside: +547.28%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.91
Upside: -47.64%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $21.37
Upside: +87.18%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $26.35
Upside: +1,114.42%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $17.35
Upside: +95.97%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.49
Upside: +2,114.77%